SCHEMBL965249

SCHEMBL965249

CC(C)CCCCCOC(=O)Nc1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.56
SORT1 Q99523 1/20 0.49
LMNA P02545 3/20 0.48
POLB P06746 1/20 0.48
CDK2 P24941 1/20 0.48
FLT4 P35916 1/20 0.48
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 4/20 0.46
HTT P42858 1/20 0.46
HDAC3 O15379 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC9 Q9UKV0 2/20 0.46
HDAC5 Q9UQL6 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967303 0.99 CHRNA7 (0.57) CHRNA7SORT1LMNAPOLBCDK2
SCHEMBL964959 0.95 CHRNA7 (0.58) CHRNA7SORT1LMNAPOLBCDK2
SCHEMBL964915 0.90 CHRNA7 (0.54) CHRNA7SORT1ALDH1A1RAB9AHTT
SCHEMBL963993 0.86 LMNA (0.65) CHRNA7LMNAPOLBRAB9ANPC1
SCHEMBL968983 0.86 LMNA (0.65) CHRNA7LMNAPOLBRAB9ANPC1
SCHEMBL965632 0.86 LMNA (0.65) CHRNA7LMNAPOLBRAB9ANPC1
SCHEMBL963651 0.84 LMNA (0.63) CHRNA7LMNAPOLBRAB9ANPC1
SCHEMBL964143 0.83 CHRNA7 (0.62) CHRNA7LMNAPOLBALDH1A1RAB9A
SCHEMBL10595749 0.83 LMNA (0.65) CHRNA7LMNAALDH1A1RAB9ANPC1
SCHEMBL30352411 0.81 ALDH1A1 (0.53) CHRNA7LMNAALDH1A1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471775-A1 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO., LTD. (JP) 2012-07-04 EP disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L CHRNA7 2474/4885SORT1 4102/4885LMNA 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.